4.3 Article

Site-specific associations between miRNA expression and survival in colorectal cancer cases

Journal

ONCOTARGET
Volume 7, Issue 37, Pages 60193-60205

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.11173

Keywords

colon cancer; rectal cancer; miRNA; disease stage

Funding

  1. NCI [CA163683, CA48998]
  2. Utah Cancer Registry
  3. National Cancer Institute [N01-PC-67000]
  4. State of Utah Department of Health
  5. Northern California Cancer Registry
  6. Sacramento Tumor Registry

Ask authors/readers for more resources

Background: MicroRNAs (miRNA) are small non-coding RNA involved in cellular processes, including cell proliferation and angiogenesis. Thus, miRNA expression may alter survival after diagnosis with colorectal cancer (CRC). Results: Individuals diagnosed with stage 1 or stage 2 rectal cancer had worse survival than colon cancer cases diagnosed at stage 1 or stage 2. After adjustment for multiple comparisons, no miRNAs were significantly associated with disease stage. Two miRNAs infrequently expressed in the population and not previously reported were associated with survival after diagnosis with colon cancer (miR-1 HR 2.17 95% CI 1.41, 3.36; and miR-101-3p HR 3.51 95% CI 1.72, 7.15). Among those diagnosed with rectal cancer, 201 miRNAs were associated with survival when the FDR q value was < 0.05. Assessment of 105 previously reported miRNAs associated with prognosis showed that four miRNAs influenced colon cancer survival and 17 influenced survival after a diagnosis with rectal cancer when raw p values were considered. Patients and Methods: This study includes data from population-based studies of CRC conducted in Utah and the Kaiser Permanente Medical Care Program. A total of 1893 carcinoma and normal paired colorectal mucosa tissue samples were run using the Agilent Human miRNA Microarray V19.0. We assessed miRNA differential expression between paired carcinoma and normal colonic mucosa tissue with CRC-specific survival evaluating stage and site-specific associations after adjusting for age, sex, microsatellite instability tumor status, and AJCC stage. Conclusions: MiRNAs dysregulated for both colon and rectal cancer had a greater impact on survival after a diagnosis with rectal cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Urology & Nephrology

The Role of Health Insurance in Patient Reported Satisfaction with Bladder Management in Neurogenic Lower Urinary Tract Dysfunction Due to Spinal Cord Injury

Temitope Rude, Odinachi Moghalu, John Stoffel, Sara Lenherr, Jeremy B. Myers, Sean Elliott, Blayne Welk, Jennifer S. Herrick, Angela P. Presson, David A. Ginsberg

Summary: The study found an association between insurance coverage and the type of bladder management following spinal cord injury, with publicly insured patients more likely to use indwelling catheters. However, insurance status did not impact bladder symptoms or quality of life when controlling for bladder management.

JOURNAL OF UROLOGY (2021)

Article Cardiac & Cardiovascular Systems

Factors associated with antihypertensive monotherapy among US adults with treated hypertension and uncontrolled blood pressure overall and by race/ethnicity, National Health and Nutrition Examination Survey 2013-2018

Alexander R. Zheutlin, Catherine G. Derington, Jordan B. King, Ransmond O. Berchie, Jennifer S. Herrick, Dave L. Dixon, Jordana B. Cohen, Daichi Shimbo, Ian M. Kronish, Joseph J. Saseen, Paul Muntner, Andrew E. Moran, Adam P. Bress

Summary: Combination antihypertensive therapy is underused, especially in certain race/ethnic groups, in the treatment of hypertension in the United States. Factors associated with monotherapy use despite uncontrolled blood pressure include higher systolic blood pressure, younger age, recent healthcare visits, higher body mass index, and the presence of heart failure.

AMERICAN HEART JOURNAL (2022)

Article Medicine, General & Internal

Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment

Zachary A. Marcum, Jordana B. Cohen, Chong Zhang, Catherine G. Derington, Tom H. Greene, Lama Ghazi, Jennifer S. Herrick, Jordan B. King, Alfred K. Cheung, Nick Bryan, Mark A. Supiano, Joshua A. Sonnen, William S. Weintraub, Jeff Williamson, Nicholas M. Pajewski, Adam P. Bress

Summary: The use of antihypertensive medications that stimulate type 2 and 4 angiotensin II receptors is associated with a lower risk of dementia. This study examines the impact of exclusively stimulating vs inhibiting antihypertensive medication regimens on mild cognitive impairment (MCI) or dementia. The findings suggest that prevalent users of stimulating medications had lower rates of cognitive impairment.

JAMA NETWORK OPEN (2022)

Article Cardiac & Cardiovascular Systems

Randomized evaluation of decision support interventions for atrial fibrillation: Rationale and design of the RED-AF study

Aubrey E. Jones, Madeleine M. McCarty, Juan P. Brito, Peter A. Noseworthy, Kerri L. Cavanaugh, Kenzie A. Cameron, Geoffrey D. Barnes, Benjamin A. Steinberg, Daniel M. Witt, George H. Crossley, Rod Passman, Preeti Kansal, Ian Hargraves, Monika Schmidt, Elizabeth Jackson, Adriana Guzman, Anthony Ariotti, Mandy L. Pershing, Jennifer Herrick, Victor M. Montori, Angela Fagerlin, Elissa M. Ozanne

Summary: This study aims to compare the effectiveness of patient decision aid (PDA) and encounter decision aid (EDA) in shared decision making. The study will recruit atrial fibrillation (AF) patients and their managing clinicians for stroke prevention strategies in a randomized controlled trial. The results will contribute to improving AF outcomes and patient experiences with stroke prevention strategies.

AMERICAN HEART JOURNAL (2022)

Article Clinical Neurology

Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow Secondary Analysis of the SPRINT MIND Randomized Clinical Trial

Sudipto Dolui, John A. Detre, Sarah A. Gaussoin, Jennifer S. Herrick, Danny J. J. Wang, Manjula Kurella Tamura, Monique E. Cho, William E. Haley, Lenore J. Launer, Henry A. Punzi, Anjay Rastogi, Carolyn H. Still, Daniel E. Weiner, Jackson T. Wright, Jeff D. Williamson, Clinton B. Wright, R. Nick Bryan, Adam P. Bress, Nicholas M. Pajewski, Ilya M. Nasrallah

Summary: Intensive antihypertensive treatment is associated with increased cerebral perfusion, particularly in patients with a history of cardiovascular disease.

JAMA NEUROLOGY (2022)

Review Medicine, General & Internal

Exfoliation Syndrome in Baja Verapaz Guatemala: A Cross-Sectional Study and Review of the Literature

Chase Paulson, Samuel C. Thomas, Orlando Gonzalez, Samuel Taylor, Cole Swiston, Jennifer S. Herrick, Lori McCoy, Karen Curtin, Craig J. Chaya, Brian C. Stagg, Barbara M. Wirostko

Summary: This study is the largest epidemiological study of exfoliation syndrome (XFS) and exfoliation glaucoma (XFG) in the Baja Verapaz region of Guatemala among individuals seeking eye exams and interventions. The study found a high prevalence of XFS/XFG, particularly among individuals in rural areas and those who speak the Mayan language.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Medicine, General & Internal

Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT)

Jordana B. Cohen, Zachary A. Marcum, Chong Zhang, Catherine G. Derington, Tom H. Greene, Lama Ghazi, Jennifer S. Herrick, Jordan B. King, Alfred K. Cheung, Nick Bryan, Mark A. Supiano, Joshua A. Sonnen, William S. Weintraub, Daniel Scharfstein, Jeff Williamson, Nicholas M. Pajewski, Adam P. Bress

Summary: This observational cohort study aimed to evaluate the cognitive outcomes of individuals at risk for mild cognitive impairment and probable dementia after initiating an ARB- vs ACEI-based antihypertensive regimen. The study found no significant difference in the rate of amnestic MCI or PD among new users of ARB compared with ACEI.

JAMA NETWORK OPEN (2022)

Article Cardiac & Cardiovascular Systems

Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019

Alexander R. Zheutlin, Catherine G. Derington, Jennifer S. Herrick, Robert S. Rosenson, Bharat Poudel, Monika M. Safford, Todd M. Brown, Elizabeth A. Jackson, Mark Woodward, Stephanie Reading, Kate Orroth, Jason Exter, Salim S. Virani, Paul Muntner, Adam P. Bress

Summary: This study investigated lipid-lowering therapy (LLT) among US veterans after myocardial infarction or elective coronary revascularization. The results showed that less than half of the patients received LLT intensification within one year, indicating a missed opportunity to reduce cardiovascular disease risk.

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2022)

Article Peripheral Vascular Disease

Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial

Catherine G. Derington, Adam P. Bress, Andrew E. Moran, William S. Weintraub, Jennifer S. Herrick, William C. Cushman, Ian M. Kronish, Barry Stults, Daichi Shimbo, Paul Muntner, Tom Greene, Jeffrey T. Bates, Tara I. Chang, Lois Anne Katz, Shakaib U. Rehman, Christianne L. Roumie, Leonardo Tamariz, Jordan B. King

Summary: In the SPRINT study, the use of ACE inhibitors or ARBs, thiazide diuretics, and calcium channel blockers in combination is favored to target systolic blood pressure (SBP) < 120 mm Hg, instead of using ACE/ARB monotherapy to target SBP < 140 mm Hg.

HYPERTENSION (2023)

Article Peripheral Vascular Disease

Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial

Jordan B. King, Catherine G. Derington, Jennifer S. Herrick, Joshua A. Jacobs, Alexander R. Zheutlin, Molly B. Conroy, William C. Cushman, Adam P. Bress

Summary: This study aimed to assess the availability of commercially available single-pill combination (SPC) antihypertensive products for achieving an intensive systolic blood pressure goal of <120 mm Hg. The results showed that most participants in the intensive treatment arm were using antihypertensive regimens that are not available as class-equivalent SPC products. Therefore, improvements in the product landscape are needed to achieve the desired results in real-world settings and reduce medication burden.

HYPERTENSION (2023)

Article Peripheral Vascular Disease

Hypertension Statistics for US Adults: An Open-Source Web Application for Analysis and Visualization of National Health and Nutrition Examination Survey Data

Byron C. Jaeger, Ligong Chen, Kathryn Foti, Shakia T. Hardy, Adam P. Bress, Sean P. Kane, Lei Huang, Jennifer S. Herrick, Catherine G. Derington, Bharat Poudel, Ashley Christenson, Lisandro D. Colantonio, Paul Muntner

Summary: A web-based application was developed to provide hypertension statistics for US adults using data from the US National Health and Nutrition Examination Survey. The study found that the mean systolic blood pressure decreased from 123 mm Hg in 1999-2000 to 120 mm Hg in 2009-2010 and then increased to 123 mm Hg in 2017-2020. The age-adjusted prevalence of hypertension was 47.9% in 1999-2000, 43.0% in 2009-2010, and 44.7% in 2017-2020. The study also estimated that 115.3 million US adults had hypertension in 2017-2020.

HYPERTENSION (2023)

Article Cardiac & Cardiovascular Systems

Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed-Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020

Catherine G. G. Derington, Adam P. P. Bress, Jennifer S. S. Herrick, Joshua A. A. Jacobs, Alexander R. R. Zheutlin, Ransmond O. O. Berchie, Molly B. B. Conroy, William C. C. Cushman, Jordan B. B. King

Summary: It is found that only one-third of hypertensive patients in the US market can be satisfied with the currently available fixed-dose combination antihypertensive products, indicating the need for further improvement in the pharmaceutical product landscape.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Article Peripheral Vascular Disease

Evidence for Age Bias Contributing to Therapeutic Inertia in Blood Pressure Management: A Secondary Analysis of SPRINT

Alexander R. Zheutlin, Daniel K. Addo, Joshua A. Jacobs, Catherine G. Derington, Jennifer S. Herrick, Tom Greene, Eric L. Stulberg, Dan R. Berlowitz, Jeff D. Williamson, Nicholas M. Pajewski, Mark A. Supiano, Adam P. Bress

Summary: Despite evidence supporting the benefits of intensive blood pressure management, older adults have the lowest rates of blood pressure control. The association between age and therapeutic inertia was determined in the SPRINT study, with older age found to be associated with greater therapeutic inertia independent of physical or cognitive function. This suggests age bias in hypertension management.

HYPERTENSION (2023)

Article Cardiac & Cardiovascular Systems

New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT

Jordan B. King, Ransmond O. Berchie, Catherine G. Derington, Zachary A. Marcum, Daniel O. Scharfstein, Tom H. Greene, Jennifer S. Herrick, Joshua A. Jacobs, Alexander R. Zheutlin, Adam P. Bress, Jordana B. Cohen

Summary: This study compared the effects of new users of ARBs versus ACEIs on cardiovascular disease events and death. The results showed similar rates of cardiovascular disease events between the two groups, with lower death rates associated with ARBs. There were subgroup differences in the effects of ARBs versus ACEIs.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Article Cardiac & Cardiovascular Systems

The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl

Catherine G. Derington, Adam P. Bress, Jennifer S. Herrick, Wenjun Fan, Nathan D. Wong, Katherine E. Andrade, Jonathan Johnson, Sephy Philip, David Abrahamson, Lixia Jiao, Deepak L. Bhatt, William S. Weintraub

Summary: Treating all eligible adults with icosapent ethyl as part of the REDUCE-IT trial can prevent a substantial number of ASCVD events, although there are significant medication costs involved. The indirect cost savings from event prevention may outweigh the incurred direct costs.

AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

No Data Available